MPA Makes PBAC Submission

An eraser is used to erase a depiction of cancerous cells

MPA made a submission to the PBAC for the consideration of the reimbursement of Nivolumab (Opdivo) and ipilumimab (Yervoy) and we thank all those that contributed their stories. Real stories provide real insights and these are invaluable! The PBAC will meet in March to consider this treatment option for reimbursement and we will advise you of the outcomes once we have any news. MPA maintains that all patients deserve access to the best evidence based treatments available.